IL-33 and thymus recovery after transplant with ATG lymphoablation
Official title: Interleukin-33 driven thymopoiesis in allograft recipients treated with lymphoablation
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11446704 · Data updated 2026-11-12
A new study aims to understand how a molecule called IL-33 helps the thymus rebuild the immune system after transplant patients receive lymphocyte-depleting therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | August 19, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $802,749 |
| NIH project number | 1R01AI195676-01A1 |
| Project ID | NIH-11446704 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients who have had solid organ transplants and receive lymphocyte-depleting induction therapy (ATG) may benefit from advances in immune reconstitution.
✕Less likely to help
The study uses animal models and focuses on basic mechanisms that may not directly translate to immediate patient care.
What this research studies
In people who have had a transplant, drugs like ATG reduce immune cells to prevent rejection. This project looks at how the thymus restarts T cell production and how IL-33 from the donor graft influences this process. Researchers will use a mouse heart transplant model and a mouse version of ATG to explore the role of IL-33 in thymopoiesis and T cell recovery. The findings could reveal targets to improve immune reconstitution and reduce infection or rejection risks after transplantation.
Why it matters
Potential benefit: If successful, the work could lead to better strategies to restore a healthy immune system after transplant, potentially lowering infection and cancer risks.
How similar studies have gone: Previous work shows IL-33 can influence thymic T cell development, but this project investigates its specific role after ATG in transplantation, which is still under exploration.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Valujskikh, Anna — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Valujskikh, Anna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.